Outcomes of different treatment opproaches for gastro-oesophageal reflux disease
Gastro-oesophageal reflux disease (GORD) is a common condition affecting around 20% of the adult population of industrialized countries1. In a recent population-based study from Sweden as much as 45% of the adult population suffered from reflux symptoms, and 15% had erosive oesophagitis on endoscopy2. A systematic review of the literature clearly demonstrated a significant increase of reflux symptoms and GORD in US and European populations. Based on these epidemiological data, optimizing the initial and long-term management of this disease has beyond, doubt high priority.
KeywordsPublic Health Internal Medicine Systematic Review Adult Population Industrialize Countries1
Unable to display preview. Download preview PDF.
- 1.Locke GR, Talley NJ, Fett SL et al. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted county., Gastroenterology. 1997;112:448–56.Google Scholar
- 6.Hansen NA, Bergheim R, Fagertun H et al. A randomised prospective study comparing the effectiveness of esomeprazole treatment strategies in clinical practice for 6 months in the management of patients with symptoms of gastroesophageal reflux disease. Int J Clin Pract. 2005;59:665–71.CrossRefGoogle Scholar
- 14.Malfertheiner P, Lind T, Willich S et al. Prognostic influence of Barrett’s oesophagus and Helicobacter pylori infection on healing of erosive gastro-oesophageal reflux disease (GORD) and symptom resolution in non-erosive GORD: report from the ProGORD study. Gut. 2005;54:746–51.PubMedCrossRefGoogle Scholar
- 21.Bardhan KD, Müller-Lissner S Bigard MS et al. Symptomatic gastro-oesophageal reflux disease: double-blinded controlled study of intermittent treatment with omeprazole or ranitidine. Br Med J 1999;318:502–7.Google Scholar
- 25.Johnson DA, Benjamin SB, Vakil NB et al. Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: a randomized, double-blind, placebo-controlled study of efficacy and safety. Am J Gastroenterol. 2001;96:27–34.PubMedCrossRefGoogle Scholar
- 26.Vakil NB, Shaker R, Johnson DA et al. The new proton pump inhibitor esomeprazole is effective as a maintenance therapy in GERD patients with healed erosive esophagitis: a 6-month, randomized, double-blind, placebo-controlled study of efficacy and safety. Aliment Pharmacol Ther. 2001;15:927–35.PubMedCrossRefGoogle Scholar